Assessing the impact of medication use on trends in major coronary risk factors in older British men: A cohort study

European Journal of Preventive Cardiology

Volumn 17, Issue 5, 2010, Pages 502-508

  Hardoon, Sarah L ^a   Whincup, Peter H ^b   Goya Wannamethee, S ^a   Lennon, Lucy T ^a   Capewell, Simon ^c   Morris, Richard W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

antihypertensive medication; blood pressure; cholesterol; epidemiology; lipid regulating medication; time trends

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD PRESSURE; COHORT ANALYSIS; CORONARY RISK; DRUG USE; DYSLIPIDEMIA; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGE FACTORS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CHOLESTEROL; CHOLESTEROL, HDL; COHORT STUDIES; CORONARY ARTERY DISEASE; DRUG UTILIZATION; DYSLIPIDEMIAS; GREAT BRITAIN; HEALTH BEHAVIOR; HUMANS; HYPERTENSION; HYPOLIPIDEMIC AGENTS; LINEAR MODELS; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 78049250795     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e3283378865     Document Type: Article

References (43)

1. British Heart Foundation Statistics Database: Coronary heart disease statistics. www.heartstats.org. [Last accessed 20 September 2008].
2. Hardoon SL, Whincup PH, Lennon LT, Wannamethee SG, Capewell S, Morris RW. How much of the recent decline in the incidence of myocardial infarction in British men can be explained by changes in cardiovascular risk factors? Evidence from a prospective population-based study. Circulation 2008; 117: 598–604.
3. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, Fortmann S, Sans S, Tolonen H, et al Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet 2000; 355: 675–687.
4. Capewell S, Morrison CE, McMurray JJ. Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart 1999; 81: 380–386.
5. Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation 2004; 109: 1101–1107.
6. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462–1536.
7. Carleton RA, Dwyer J, Finberg L, Flora J, Goodman DS, Grundy SM, et al Report of the expert panel on population strategies for blood cholesterol reduction. A statement from the National Cholesterol Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health. Circulation 1991; 83: 2154–2232.
8. Office for National Statistics. Prescription cost analysis 2007. Leeds: The Information Centre; 2008.
9. Walker M, Whincup PH, Shaper AG. The British Regional Heart Study 1975–2004. Int J Epidemiol 2004; 33: 1185–1192.
10. Whincup PH, Bruce NG, Cook DG, Shaper AG. The Dinamap 1846SX automated blood pressure recorder: comparison with the Hawksley random zero sphygmomanometer under field conditions. J Epidemiol Community Health 1992; 46: 164–169.
11. Wannamethee SG, Shaper AG. Taking up regular drinking in middle age: effect on major coronary heart disease events and mortality. Heart 2002; 87: 32–36.
12. Shaper AG, Wannamethee G, Weatherall R. Physical activity and ischaemic heart disease in middle-aged British men. Heart 1991; 66: 384–394.
13. Office for National Statistics. Key health statistics from general practice 1998. UK: Crown; 2000.
14. Klungel OH, de Boer A, Paes AH, Herings RM, Seidell JC, Bakker A. Agreement between self-reported antihypertensive drug use and pharmacy records in a population-based study in The Netherlands. Pharm World Sci 1999; 21: 217–220.
15. Thomas MC, Walker M, Lennon LT, Thomson AG, Lampe FC, Shaper AG, et al Non-attendance at re-examination 20 years after screening in the British Regional Heart Study. J Public Health Med 2002; 24: 285–291.
16. Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it. Int J Epidemiol 2005; 34: 215–220.
17. Evans B, Primatesta P. Health Survey for England 1998. London: The Stationary Office; 1999.
18. Antikainen RL, Moltchanov VA, Chukwuma C Sr, Kuulasmaa KA, Marques-Vidal PM, et al Trends in the prevalence, awareness, treatment and control of hypertension: the WHO MONICA Project. Eur J Cardiovasc Prev Rehabil 2006; 13: 13–29.
19. Tunstall-Pedoe H, Connaghan J, Woodward M, Tolonen H, Kuulasmaa K. Pattern of declining blood pressure across replicate population surveys of the WHO MONICA project, mid-1980s to mid-1990s, and the role of medication. BMJ 2006; 332: 629–635.
20. Joint Health Surveys Unit. Health Survey for England 2006. Cardiovascular disease and risk factors. Leeds: The Information Centre; 2008.
21. Arnett DK, Jacobs DR Jr., Luepker RV, Blackburn H, Armstrong C, Claas SA. Twenty-year trends in serum cholesterol, hypercholesterolemia, and cholesterol medication use: the Minnesota Heart Survey, 1980–1982 to 2000–2002. Circulation 2005; 112: 3884–3891.
22. Young F, Critchley JA, Capewell S. Attribution of coronary mortality declines in the USA between 1980 and 2000 to primary and secondary prevention. Euro PRevent 2009 conference. Stockholm, May 2009 [Abstract 543].
23. Campbell SC, Moffatt RJ, Stamford BA. Smoking and smoking cessation-The relationship between cardiovascular disease and lipoprotein metabolism: a review. Atherosclerosis 2008; 201: 225–235.
24. Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart 2008; 94: 706–714.
25. National Food Survey 2000. https://statistics.defra.gov.uk/esg/publications/nfs/2000. [Last Accessed 27 March 2009].
26. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–1278.
27. De Boer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003; 10: S1–S10.
28. Rose G. Strategy of prevention: lessons from cardiovascular disease. BMJ 1981; 282: 1847–1851.
29. Uusitalo U, Feskens EJM, Tuomilehto J, Dowse G, Haw U, Fareed D, et al Fall in total cholesterol concentration over five years in association with changes in fatty acid composition of cooking oil in Mauritius: cross sectional survey. BMJ 1996; 313: 1044–1046.
30. Manuel DG, Lim J, Tanuseputro P, Anderson GM, Alter DA, Laupacis A, et al Revisiting Rose: strategies for reducing coronary heart disease. BMJ 2006; 332: 659–662.
31. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326: 1419.
32. Rose GA. The strategy of preventive medicine. Oxford: Oxford University Press; 1992.
33. Emberson J, Whincup P, Morris R, Walker M, Ebrahim S. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 2004; 25: 484–491.
34. DeWilde S, Carey IM, Richards N, Whincup PH, Cook DG. Trends in secondary prevention of ischaemic heart disease in the UK 1994–2005: use of individual and combination treatment. Heart 2008; 94: 83–88.
35. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913.
36. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. Lancet 2007; 370: 1829–1839.
37. Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens 2002; 20: 2099–2110.
38. National Centre for Social Research: Health Survery for England 2006. Adult trend tables. http://www.ic.nhs.uk/webfiles/publications/HSE06/. [Last Accessed 4 December 2008].
39. Falaschetti E, Chaudhury M, Mindell J, Poulter N. Continued improvement in hypertension management in England: results from the Health Survey for England 2006. Hypertension 2009; 53: 480–486.
40. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension 2007; 49: 69–75.
41. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D etal; DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001; 344: 3–10.
42. Department of Environment, Farming and Rural Affairs. Family food in 2007. London: Crown; 2008.
43. Ueshima H, Stamler J, Elliott P, Chan Q, Brown IJ, Carnethon MR, et al Food omega-3 fatty acid intake of individuals (total, linolenic acid, long-chain) and their blood pressure: INTERMAP study. Hypertension 2007; 50: 313–319.